Evolution of Treatment Products
Adapted from: Global NMO Training 2016 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael This second module in the Treatment Products eLearning Program explains the evolution of products for the treatment of bleeding disorders, from products derived from blood to artificially produced clotting factor concentrates (CFCs) with extended half-lives (EHL). […]
New Approaches to Tolerance: Oral Delivery of Blood Clotting Factors Bioencapsulated in Plant Cells
In the Monday morning session entitled Inhibitors: Clinical Aspects, Henry Daniell presents current advances in the development of new, affordable systems for oral delivery of clotting factors.
Guide for the Assessment of Clotting Factor Concentrates
The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment of hemophilia. It discusses the factors that contribute to the quality, safety, and efficacy of hemophilia treatment products and, in particular, the provisions made for ensuring that these products are free of viruses. It covers […]
Proceedings of the WFH’s Tenth Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Tenth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which brings together patient groups, healthcare providers, researchers, regulators, industry representatives, and not-for-profit fractionators.
Factor Replacement Therapy Schematic
This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking, and how infusion of replacement therapy works to achieve normal levels of blood clotting. It also illustrates the clotting factor cascade and highlights the points in the cascade where each type of hemophilia treatment product […]
What is the Ideal Factor Trough Level?
At the WFH 2017 Global Forum in Montréal, David Page led a discussion between Alok Srivastava (India), Mark Skinner (USA), Margaret Ragni (USA), and Cedric Hermans (Belgium) to define the ideal clotting factor trough level for people with hemophilia, particularly in light of recent and ongoing advances in treatment options. Additional Information To learn more […]
Haemophilia – New Technologies
In the Wednesday morning session on new technologies, Dan Hart presents an overview of technologies promising to impact the care of people with hemophilia.
Essential Medicines List, Orphan Drugs, and Paid Plasma
In the Tuesday morning WFH session on global surveillance and collaboration, Brian O’Mahony, provides his vision for the role of the WFH in ensuring adequate access to a safe supply of hemophilia treatment.
Blood Safety and Donor Deferrals: The history and ongoing risk evaluation
In the Tuesday morning WFH session on global surveillance and collaboration, David Page, discusses donor deferrals, issues of blood safety and the role of the WFH.
Bleeding and Response to Treatment: How to define a bleed
In the Thursday morning session on bleeding and response to treatment, David Page discusses how to define a bleed.
Medical Plenary: Hemophilia treatment in 2030
In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.
WFH Webinar: Treatment Options for Hemophilia in the Developing World
On December 16, 2016, the WFH in collaboration with the ISTH, recorded a live interactive webinar on the challenges and opportunities of treatment options for hemophilia in the developing world, now available for viewing here. Introduced by Marijke van den Berg, Rolf Ljung opened with a summary of the lessons learned from decades of experience […]